CHCWM – Cancer & Hematology Centers of West Michigan

HM06-19-26 (Helsinn)

HM06-19-26 (Helsinn)

 Description:   Phase I/II Study of the Selective RET Inhibitor TAS0953/HM06 in Patients

with Advanced Solid Tumors with RET gene abnormalities.

Mechanism of Action: RET Inhibitor

Target Patient Population:  Any tumor type with RET gene abnormalities

Study Design:  Study drug is given orally